Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Kiora Pharmaceuticals Inc

NASDAQ: KPRX · Life Sciences · 3 alerts · CIK 1372514

Share price
$0.9820Close, Nov 16
Market cap
$4.34M
Shares outstanding
4.42MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kiora Pharmaceuticals Inc filings on SEC EDGAR ↗

7:02 AM ET 8-K
Financial Results

Kiora Pharmaceuticals Financial Results

Kiora Pharmaceuticals reported third quarter 2026 financial results and highlighted the strategic in-licensing of KIO-401, a late-stage oral neuroprotective asset for retinal diseases. The company ended the quarter with $16.3 million in cash and is preparing for a Phase 3 registration trial for KIO-401 in patients with Central Retinal Artery Occlusion (CRAO).

“The addition of KIO-401 transforms Kiora into a late-stage retinal therapeutics company. We are building on the significant amount of CMC, non-clinical and clinical data that already exists on KIO-401 through Senju’s previous and ongoing efforts. With exclusive rights outside Asia, we are preparing for a single, phase 3, registration trial of KIO-401 in patients across the United States, Europe and other territories.”

Brian M. Strem, Ph.D., President and Chief Executive Officer
7:01 AM ET 10-Q
Financial Results

Kiora Pharmaceuticals Q3 2026 Results: Net Loss of $1.75M

Kiora Pharmaceuticals reported a net loss of $1.75 million for the third quarter of 2026, compared to a small net income of $0.03 million in the prior year period. While the company recognized $1.0 million in collaboration revenue, total operating expenses increased significantly due to a $1.77 million unfavorable swing in the fair value of contingent consideration.

Key figure
Net loss $1.75M
7:04 AM ET 8-K
Licensing Deal

Kiora Pharmaceuticals Licensing Deal with Senju Pharmaceutical Co., Ltd. Worth $3.5M

Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical to develop and commercialize KIO-401, a late-stage oral small-molecule calpain inhibitor for ophthalmic diseases, in all territories outside of Asia. Kiora will pay an upfront fee of $3.5 million, low teen millions upon technology transfer, and up to $168.5 million in potential regulatory and commercial milestones, plus single-digit royalties.

Value
$3.5M
Counterparty
Senju Pharmaceutical Co., Ltd.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.